Clinical trials: Esophagogastric Cancer
Esophageal Neoplasms, Stomach Neoplasms
Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma
Patients with advanced oesophagogastric cancer (OCG) have a very poor prognosis. After progression on first line therapy, second line chemotherapy with paclitaxel and a VEGF-R2 targeting antibody has a proven benefit on survival.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
- Trial name
- REPEAT (NCT02406170)
- Testing
- Regorafenib, Paclitaxel
- Where
- Netherlands
- Volunteers
- 47 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophagogastric Junction Disorder, Neoplasms
Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
Patients with histologically confirmed esophagogastric junction adenocarcinoma with pre-operative staging cT3-4N+M0，aged between 18-75 years old, with adequate organ function and having an Eastern Cooperative Oncology Group…
- Trial name
- NCT03961841
- Testing
- chemoradiation with weekly 5Fu and oxaliplatin, Perioperative mFLOT, Perioperative FOLFOX
- Volunteers
- 900 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 (PD-L1 inhibitor), anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced…
- Trial name
- NCT04891900
- Testing
- TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Henan Cancer Hospital
Esophagogastric Cancer
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
In this study the investigators aim to: 1) confirm the objective response rate (ORR) observed in the investigators initial study for patients with the TSER*2/*2 genotype 2) determine whether PEMOX regimen is more worthy of future…
- Trial name
- NCT02296671
- Testing
- Pemetrexed, Oxaliplatin, Leucovorin
- Sponsor
- Washington University School of Medicine
Esophageal Cancer, Gastric Cancer
Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
The main purpose of this study is to test the safety and tolerability and effectiveness of a new treatment, EMD 72000 (matuzumab), for advanced oesophagogastric cancer in combination with the chemotherapy regimen ECX (epirubicin…
- Trial name
- NCT00113581
- Testing
- EMD 72000 (matuzumab) + ECX
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumors, Gastric Cancer
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer
- Trial name
- NCT05275062
- Testing
- IM92 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Adenocarcinoma, Stomach Cancer
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
This prospective study includes patients with histologically proven cancer of the esophagogastric junction (Siewert Type II and III) and the stomach.
- Conditions
- Adenocarcinoma, Stomach Cancer, Cancer of Esophagogastric Junction
- Trial name
- NCT00800969
- Testing
- FDG-PET-CT
- Where
- Switzerland
- Sponsor
- University of Zurich
Esophageal Cancer, Gastric Cancer
Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)
Esophageal cancer and cancers of the gastroesophageal junction (GEJ) are among the most common malignancies worldwide. The outcome for these patients remains very poor.
- Conditions
- Esophageal Cancer, Gastric Cancer, Oligometastatic Disease
- Trial name
- TORO (NCT06668454)
- Testing
- Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- University Health Network, Toronto
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
- Conditions
- Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma
- Trial name
- P102 (NCT02013154)
- Testing
- DKN-01 150 mg, Paclitaxel, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 151 people
- Sponsor
- Leap Therapeutics, Inc.
Gastric Cancer, Cancer of the Stomach
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic…
- Conditions
- Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
- Trial name
- NCT03662659
- Testing
- BMS-986213, Nivolumab, XELOX
- Where
- 79 sites in United States, Argentina and 15 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Perianastomotic Drain After Gastrectomy (DRAG)
Gastric cancer ranks as the fifth most common and fifth most lethal cancer globally. For patients with AJCC stages IB to IIIC, representing the majority of cases, the current gold standard of surgical treatment involves total…
- Trial name
- DRAG (NCT04288661)
- Testing
- No drain placement
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- THEODOROU DIMITRIOS